S-4/A Filing Advances Oak Hill Bio Merger as Scalar Flags $9M Net Cash Correction
RACC is trading near its 52-week low of $10.21 (7.0% above the low).
Summary
RACC's S-4/A discloses a $9M upward correction to Oak Hill Bio's pro forma net cash and confirms the merger is progressing toward a shareholder vote, with shares trading above $24.
Key Events · M&A and Partnerships · RACC
-
S-4 Amendment No. 1 Filed
On September 25, 2026, RACC filed Amendment No. 1 to its S-4 registration statement, moving the Oak Hill Bio merger closer to effectiveness and a shareholder vote.
-
Scalar Corrects Pro Forma Net Cash
Fairness-opinion provider Scalar identified a $9.0 million upward correction to Oak Hill Bio's pro forma net cash on August 6, 2026, which increased the implied equity value reference range but did not change Scalar's fairness conclusion.
-
RACC Board Reviews Correction
The RACC Board reviewed the Scalar correction on August 11, 2026, and determined no further action was necessary; the original board approvals remain unchanged.
-
Share Price More Than Doubles
RACC Class A shares closed at $24.60 on August 19, 2026, versus $11.02 on July 24, 2026 (the last trading day before the merger announcement), reflecting strong market enthusiasm.
Analysis · RACC · Life Sciences
The Oak Hill Bio merger takes a step closer to a shareholder vote with the filing of Amendment No. 1 to the S-4 registration statement. Central to the update is a $9.0 million upward correction to Oak Hill Bio's pro forma net cash, identified by fairness-opinion provider Scalar on August 6 and reviewed by the RACC Board on August 11. While the correction raised the implied equity value reference range in Scalar's analysis, it did not alter the fairness conclusion or the board's approval. The filing also notes that RACC shares traded at $24.60 on August 19, more than double the $11.02 pre-announcement price, signaling robust market enthusiasm for the deal. The merger still requires shareholder approval, Nasdaq listing, and other closing conditions, with a termination date of January 26, 2027, extendable to April 26, 2027.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.5% of the 1629 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.59%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RACC was trading at $10.92 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $99.4M. The 52-week trading range was $10.21 to $33.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.